tiprankstipranks
Trending News
More News >

ReShape Lifesciences Raises Equity to Avoid Delisting

Story Highlights
ReShape Lifesciences Raises Equity to Avoid Delisting

Don’t Miss TipRanks’ Half-Year Sale

ReShape Lifesciences ( (RSLS) ) has issued an announcement.

On May 28, 2025, ReShape Lifesciences Inc. received a notice from Nasdaq regarding potential delisting due to non-compliance with the minimum stockholders’ equity requirement of $2.5 million. However, through the sale of shares between June 3 and June 9, 2025, the company raised its stockholders’ equity above the required threshold. Despite this improvement, delisting is still a possibility, pending a decision from a Nasdaq Hearings Panel.

Spark’s Take on RSLS Stock

According to Spark, TipRanks’ AI Analyst, RSLS is a Underperform.

ReShape Lifesciences is facing significant financial challenges, with persistent losses, negative equity, and cash flow issues. The technical indicators show a bearish trend with potential oversold conditions. Valuation is poor due to a negative P/E ratio. Despite some positive developments highlighted in the earnings call, such as revenue growth and cost reductions, the overall outlook remains concerning due to financial instability and competitive pressures. The recent board resignation further complicates the situation by potentially affecting compliance and investor confidence.

To see Spark’s full report on RSLS stock, click here.

More about ReShape Lifesciences

ReShape Lifesciences Inc. operates in the medical device industry, focusing on products and services related to weight loss and metabolic health.

Average Trading Volume: 2,996,580

Technical Sentiment Signal: Sell

Current Market Cap: $6.85M

See more insights into RSLS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1